Merck & Company Inc (MRK BE) stock market data APIs
€118.9716
0(0%)
as of December 22, 2025
Try our APIs with
free plan!
Merck & Company Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for MRK.BE.
Prev. Close
118.9716
Open
118.9716
High
118.9716
Low
118.9716
52 wk Range
104-148.275
Market Cap
97 608 M
EPS
2.07
Dividends (Yield)
0.0134
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Company Inc data using free add-ons & libraries
Get Merck & Company Inc Fundamental Data
Merck & Company Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-10
- EPS/Forecast: 2.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Company Inc News
New
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Abbisko Therapeutics Co., Ltd. Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimic...
Does Merck KGaA’s Rebound Reflect Its True Value After AI Partnership And CEO Change News
Wondering if Merck KGaA is a bargain hiding in plain sight or a value trap at €118.85? This article unpacks what the market is really pricing in. The stock has slipped 0.2% over the last week, but i...
Latent Labs Announces Latent-X2: AI-Generated Antibodies With Drug-Like Developability and Low Ex Vivo Immunogenicity
LONDON & SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics without iteration. Drug hunters can use Late...
Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug. Continue Reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
